EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word(s): Financing Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB) 06-Sep-2021 / 17:46 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Ad hoc announcement pursuant to Art. 53 SIX Listing Rules

Milan, Italy - September 6, 2021, 5.45 pm CEST - Newron Pharmaceutical S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 4 under its financing agreement with the European Investment Bank (EIB) that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria. The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe. Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Company's development programs in diseases of the central nervous system. The first three tranches of the loan totaling EUR 25 million were received by Newron in 2019 and 2020. In connection with Tranche 4, EIB has received warrants entitling it to purchase up to 151,344 ordinary shares of Newron at an exercise price of EUR 9.25 per share.

About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago(R)/safinamide has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Brazil, Colombia, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron's Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com

For more information Newron Stefan Weber - CEO, +39 02 6103 46 26, pr@newron.com

UK/Europe Simon Conway/ Natalie Garland-Collins, FTI Consulting, +44 (0)20 3727 1000, SCnewron@fticonsulting.com

Switzerland Valentin Handschin, IRF Reputation, +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe Anne Hennecke/Caroline Bergmann, MC Services, +49 211 52925220, newron@mc-services.eu

USA Paul Sagan, LaVoieHealthScience, +1 617 374 8800, Ext. 112, psagan@lavoiehealthscience.com

-----------------------------------------------------------------------------------------------------------------------

End of ad hoc announcement

----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      Newron Pharmaceuticals SpA 
              Via Antonio Meucci 3 
              20091 Bresso 
              Italy 
E-mail:       info@newron.com 
Internet:     www.newron.com 
ISIN:         IT0004147952 
Listed:       SIX Swiss Exchange 
EQS News ID:  1231559 
 
End of Announcement EQS Group News Service 
=------------

1231559 06-Sep-2021 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1231559&application_name=news

(END) Dow Jones Newswires

September 06, 2021 11:46 ET (15:46 GMT)